|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.50 USD | -0.95% |
|
-1.83% | -25.07% |
| 09:18pm | Zonebourse Earnings Calendar: week of July 13 to 17, 2026 |  |
| 06/07 | Evercore ISI Adjusts Abbott Laboratories Price Target to $112 From $120 | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,41,365 | 1,91,427 | 1,91,088 | 1,96,184 | 2,17,859 | 1,64,427 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -24.53% | - | - |
| Enterprise Value (EV) 1 | 2,49,166 | 1,98,318 | 1,98,871 | 2,02,693 | 2,22,266 | 1,76,116 | 1,73,284 | 1,69,386 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -20.76% | -1.61% | -2.25% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 23.3x | 19.9x | 17.4x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.32x | 3.19x | 2.97x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | 2.68x | 1.2x | 1.2x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.27x | 3x | 2.81x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.5x | 3.17x | 2.89x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 13.1x | 11.9x | 10.6x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 15.1x | 13.3x | 11.8x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 20.3x | 18.4x | 16.3x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 4.92% | 5.44% | 6.13% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.547 | 2.715 | 2.866 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.7% | 2.88% | 3.04% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 4.043 | 4.736 | 5.437 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 63% | 57.3% | 52.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,256 | 54,748 | 58,610 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,414 | 14,578 | 15,961 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,665 | 13,038 | 14,362 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 7,018 | 8,389 | 9,226 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 11,689 | 8,857 | 4,959 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 94.40 | 94.40 | 94.40 |
| Nbr of stocks (in thousands) | 17,14,968 | 17,43,574 | 17,36,059 | 17,34,455 | 17,38,834 | 17,41,813 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.35x | 3.5x | 13.13x | 2.7% | 16TCr | |
| 18.68x | 3.26x | 11.5x | 3.6% | 11TCr | |
| 16.63x | 0.19x | 11.89x | 0.78% | 5.88TCr | |
| 31.32x | 7.59x | 19.84x | 1.28% | 5.11TCr | |
| 37.59x | 2.99x | 10.28x | 2.55% | 4.16TCr | |
| 39.11x | 1.42x | 12.47x | 0.2% | 3.45TCr | |
| 29.83x | 5.32x | 16.95x | -.--% | 2.82TCr | |
| 42.48x | 7.36x | 26.56x | 0.25% | 2.53TCr | |
| 19.69x | 2.72x | 10.58x | 1.6% | 2.02TCr | |
| 23.76x | 3.47x | 12.49x | 1.22% | 2.11TCr | |
| Average | 28.24x | 3.78x | 14.57x | 1.42% | 5.51TCr | |
| Weighted average by Cap. | 25.63x | 3.55x | 13.74x | 2.02% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
